CORE--CYTOGENETICS

$250,404P30FY2002CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739 Paper 39737640 Paper 39726772 Paper 39711559 Paper 39711135 Paper 39684443 Paper 39677775 Paper 39677720 Paper 39677022 Paper 39671500 Paper 39671496 Paper 39630148 Paper 39609428 Paper 39604567 Paper 39603869 Paper 39574899 Paper 39564580 Paper 39554114 Paper 39436696 Paper 39400608 Paper 39384405 Paper 39342284 Paper 39321266 Paper 39311710 Paper 39282307 Paper 39266537 Paper 39264810 Paper 39215796 Paper 39201277 Paper 39191549 Paper 39147413 Paper 39139560 Paper 39136655 Paper 39120971 Paper 39091762 Trial NCT05073848 Trial NCT05053737 Trial NCT05006040 Trial NCT04993859 Trial NCT04988490 Trial NCT04973007 Trial NCT04963283 Trial NCT04940468 Trial NCT04925193 Trial NCT04922112 Trial NCT04916990 Trial NCT04882111 Trial NCT04866758 Trial NCT04863092 Trial NCT04634110 Trial NCT04611022 Trial NCT04565457 Trial NCT04558138 Trial NCT04544592 Trial NCT04541407 Trial NCT04535102 Trial NCT04520867 Trial NCT04486573 Trial NCT04471363 Trial NCT04408092 Trial NCT04305366 Trial NCT04300478 Trial NCT04294693 Trial NCT04208243 Trial NCT04092803 Trial NCT04091867 Trial NCT04066218 Trial NCT04042935 Trial NCT04035408 Trial NCT04028167 Trial NCT04028063 Trial NCT04001101 Trial NCT03995082 Trial NCT03976193 Trial NCT03970226 Trial NCT03958565 Trial NCT03900793 Trial NCT03891654 Trial NCT03881098 Trial NCT03781154 Trial NCT03734653 Trial NCT03617679 Trial NCT03325634 Trial NCT01886859 Trial NCT01426334 Trial NCT01232829 Trial NCT00778167 Patent 9434994 Patent 8734778 Patent 8715649 Patent 8343502 Patent 8337830 Patent 8221763 Patent 8153136 Patent 8067559 Patent 7910315 Patent 7595060 Patent 7563447 Patent 7465454 Patent 7083787

Abstract

Description: (Applicant's Description) The Cytogenetics Core offers state-of-the-art cytogenetic technology for Cancer Center members. Banding karyotype is available for numerous mammalian species and computer-based karyotyping is provided for human cells. Among the molecular techniques available, fluorescence in situ (FISH) analysis is offered in metaphase and interphase cells for single or multiple DNA targets from a variety of biological specimens. Comparative Genomic Hybridization (for human, mouse and rat specimens) and multicolor karyotyping (Multiplex-FISH) are also available. In addition to the use of commercial probes, the Cytogenetics Core has capability to prepare DNA probes according to the investigator?s needs. Scientific and technical support has been provided to Cancer Center members in experimental design of projects and a comprehensive interpretation of the data obtained in the assays is offered. A total of 31 Cancer Center members from 9 distinct Programs (Cell Biology, Tobacco Related Malignancies, Cancer Genetics, Developmental Therapeutics, Hormone Related Malignancies, Immunology and Immunotherapy, Carcinogenesis and Chemoprevention, and Pediatric Oncology), have used this facility from 1996 to 1999. Approximately 50% of the investigators have used the Core for more than a grant-year. On average, more than 1,000 procedures were performed per year, and a dramatic change from classical towards molecular techniques has been observed. The Core has been assisting Cancer Center investigators both in basic and translational aspects of cancer research. The development of new FISH probes, such as the 3p21.31 probe that usually detects deletion in lung carcinomas, the D-FISH AML/ETO probe for diagnosis of residual AML-M2, and the E2A probe for ALL, illustrates the translational focus of projects that make use of the laboratory. Mapping of DNA clones, characterization and analysis of chromosomal evolution of cell lines, identification of subtle heterozygous and homozygous deletions, and detection of gene amplifications are examples of services routinely submitted to the Core.

View original record on NIH RePORTER →